1. Loss of Somatostatin Receptor Subtype 2 in Prostate Cancer Is Linked to an Aggressive Cancer Phenotype, High Tumor Cell Proliferation and Predicts Early Metastatic and Biochemical Relapse
   Jan K. Hennigs et al, 2014, PLoS ONE CrossRef
2. Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours
   Eleonora Vitali et al, 2016, Endocr Relat Cancer CrossRef
3. Somatostatin analogs: does pharmacology impact antitumor efficacy?
   Mounira Chalabi et al, 2014, Trends in Endocrinology & Metabolism CrossRef
4. Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: Effect of mono- and bi-specific somatostatin analogs on cell growth
   M. Ruscica et al, 2014, Molecular and Cellular Endocrinology CrossRef
5. New Agonist- and Antagonist-Based Treatment Approaches for Advanced Prostate Cancer
   Y Xu et al, 2012, J Int Med Res CrossRef
6. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment
   E. Peverelli et al, 2017, Int. J. Cancer CrossRef
7. Differential molecular mechanism of docetaxel–octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells
   Laura Lattanzio et al, 2013 CrossRef
8. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors
   E. Vitali et al, 2021, Molecular and Cellular Endocrinology CrossRef
9. Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
   Kristen McClellan et al, 2022, Cancers CrossRef